731 related articles for article (PubMed ID: 28854088)
1. Precision Diagnosis and Treatment for Advanced Non-Small-Cell Lung Cancer.
Reck M; Rabe KF
N Engl J Med; 2017 Aug; 377(9):849-861. PubMed ID: 28854088
[No Abstract] [Full Text] [Related]
2. Endobronchial ultrasonography (EBUS)--its role in staging of non-small cell lung cancer and who should do it?
Andrade RS; Odell DD; D'Cunha J; Maddaus MA
J Thorac Cardiovasc Surg; 2012 Sep; 144(3):S9-13. PubMed ID: 22898528
[No Abstract] [Full Text] [Related]
3. EGFR mutations in non-small-cell lung cancer.
Hung JJ; Jeng WJ; Hsu WH; Liu JS; Wu YC
Lancet Oncol; 2010 May; 11(5):412-3; author reply 413. PubMed ID: 20434712
[No Abstract] [Full Text] [Related]
4. Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update Summary.
Hanna N; Johnson D; Temin S; Masters G
J Oncol Pract; 2017 Dec; 13(12):832-837. PubMed ID: 28850309
[No Abstract] [Full Text] [Related]
5. The cellular origins of drug resistance in cancer.
Oxnard GR
Nat Med; 2016 Mar; 22(3):232-4. PubMed ID: 26937615
[No Abstract] [Full Text] [Related]
6. Recent clinical advances in lung cancer management.
Johnson DH; Schiller JH; Bunn PA
J Clin Oncol; 2014 Apr; 32(10):973-82. PubMed ID: 24567433
[TBL] [Abstract][Full Text] [Related]
7. Emerging gene mutation targets in lung cancer.
Johnson BE
Clin Adv Hematol Oncol; 2015 Dec; 13(12):812-4. PubMed ID: 27058846
[No Abstract] [Full Text] [Related]
8. A case of residual non-small cell lung cancer cells coexisting with newly developed small cell lung cancer cells in ascitic fluid after chemotherapy for non-small cell lung cancer.
Park SH; Chi HS; Kim YJ; Cho YU; Jang S; Park CJ; Kim SW
Ann Lab Med; 2014 Mar; 34(2):163-5. PubMed ID: 24624356
[No Abstract] [Full Text] [Related]
9. Perspectives in Lung Cancer--Third Asian-pacific Conference. 11-12 September 2009, Bangkok, Thailand.
Lopes Gde L
IDrugs; 2009 Nov; 12(11):689-91. PubMed ID: 19844853
[TBL] [Abstract][Full Text] [Related]
10. Miliary brain metastases in 2 cases with advanced non-small cell lung cancer harboring EGFR mutation during gefitinib treatment.
Mochizuki S; Nishimura N; Inoue A; Murakami K; Nukiwa T; Chohnabayashi N
Respir Investig; 2012 Sep; 50(3):117-21. PubMed ID: 23021771
[TBL] [Abstract][Full Text] [Related]
11. Targeting EGFR mutation in non-small-cell lung cancer: challenges and future perspectives.
Haddad FG; Kourie HR; Kattan J
Future Oncol; 2017 Feb; 13(3):201-204. PubMed ID: 27624407
[No Abstract] [Full Text] [Related]
12. Prognostic factors in non-small cell lung cancer patients who are recommended to receive single-agent chemotherapy (docetaxel or pemetrexed) as a second- or third-line chemotherapy: in the era of oncogenic drivers and molecular-targeted agents.
Shukuya T; Ko R; Mori K; Kato M; Yagishita S; Kanemaru R; Honma Y; Shibayama R; Koyama R; Shimada N; Takahashi K
Cancer Chemother Pharmacol; 2015 Oct; 76(4):771-6. PubMed ID: 26259641
[TBL] [Abstract][Full Text] [Related]
13. Availability of EGFR mutation status at first oncology consultation for advanced non-squamous non-small cell lung cancer patients. A pilot experience from the Christie.
Evans M; Summers Y; Taylor P; Harris M; Bayman N; Faivre-Finn C; Sheikh H; Burt P; Blackhall F; Califano R
Lung Cancer; 2013 Dec; 82(3):510-1. PubMed ID: 24138902
[No Abstract] [Full Text] [Related]
14. Primary non-small cell lung cancer response upon treatment with denosumab.
Curioni-Fontecedro A; Husmann L; Soldini D; Stahel RA
Lung Cancer; 2013 Dec; 82(3):506-8. PubMed ID: 24075124
[TBL] [Abstract][Full Text] [Related]
15. Afatinib: a second-generation EGF receptor and ErbB tyrosine kinase inhibitor for the treatment of advanced non-small-cell lung cancer.
Marquez-Medina D; Popat S
Future Oncol; 2015 Sep; 11(18):2525-40. PubMed ID: 26314834
[TBL] [Abstract][Full Text] [Related]
16. Case records of the Massachusetts General Hospital. Case 31-2011. A 55-year-old man with oligometastatic lung cancer.
Lanuti M; Sequist LV; Sharma A; Mino-Kenudson M
N Engl J Med; 2011 Oct; 365(15):1426-35. PubMed ID: 21995391
[No Abstract] [Full Text] [Related]
17. Third-generation chemotherapy agents in the treatment of advanced non-small cell lung cancer: a meta-analysis.
Sculier JP; Meert AP
J Thorac Oncol; 2008 Mar; 3(3):320; author reply 320-2. PubMed ID: 18317082
[No Abstract] [Full Text] [Related]
18. First-line therapy of mutated non-small cell lung cancer: an update.
Stöhlmacher-Williams J
Onkologie; 2012; 35(5):293-9. PubMed ID: 22868512
[TBL] [Abstract][Full Text] [Related]
19. Waging war on lung cancer.
Brown E
FDA Consum; 1999; 33(3):7-8, 10-1. PubMed ID: 10443183
[No Abstract] [Full Text] [Related]
20. Manage patients with non-small cell lung cancer.
Becze E
ONS Connect; 2008 Oct; 23(10):20-1. PubMed ID: 18856090
[No Abstract] [Full Text] [Related]
[Next] [New Search]
